199 related articles for article (PubMed ID: 26932927)
1. Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor - Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region.
Goh KL; Choi MG; Hsu PI; Chun HJ; Mahachai V; Kachintorn U; Leelakusolvong S; Kim N; Rani AA; Wong BC; Wu J; Chiu CT; Shetty V; Bocobo JC; Chan MM; Lin JT
J Neurogastroenterol Motil; 2016 Jul; 22(3):355-66. PubMed ID: 26932927
[TBL] [Abstract][Full Text] [Related]
2. The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease.
Fass R; Frazier R
Therap Adv Gastroenterol; 2017 Feb; 10(2):243-251. PubMed ID: 28203282
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole.
Mermelstein J; Mermelstein AC; Chait MM
Clin Exp Gastroenterol; 2016; 9():163-72. PubMed ID: 27471402
[TBL] [Abstract][Full Text] [Related]
4. Dexlansoprazole: delayed-release orally disintegrating tablets for the treatment of heartburn associated with non-erosive gastroesophageal reflux disease and the maintenance of erosive esophagitis.
Oldfield EC; Parekh PJ; Johnson DA
Expert Rev Gastroenterol Hepatol; 2016 Oct; 10(10):1083-1089. PubMed ID: 27580358
[TBL] [Abstract][Full Text] [Related]
5. Managing gastroesophageal reflux disease - comparative efficacy and outcomes of dexlansoprazole MR.
Frye JW; Peura DA
Ther Clin Risk Manag; 2015; 11():1649-56. PubMed ID: 26586949
[TBL] [Abstract][Full Text] [Related]
6. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.
Abel C; Desilets AR; Willett K
Ann Pharmacother; 2010 May; 44(5):871-7. PubMed ID: 20371754
[TBL] [Abstract][Full Text] [Related]
7. Dexlansoprazole MR for the management of gastroesophageal reflux disease.
Behm BW; Peura DA
Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):439-45. PubMed ID: 21780890
[TBL] [Abstract][Full Text] [Related]
8. Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis.
Wittbrodt ET; Baum C; Peura DA
Clin Exp Gastroenterol; 2009; 2():117-28. PubMed ID: 21694835
[TBL] [Abstract][Full Text] [Related]
9. Dexlansoprazole - a new-generation proton pump inhibitor.
Skrzydło-Radomańska B; Radwan P
Prz Gastroenterol; 2015; 10(4):191-6. PubMed ID: 26759624
[TBL] [Abstract][Full Text] [Related]
10. Dexlansoprazole for the treatment of esophagitis and GERD.
Davies SL
Drugs Today (Barc); 2010 Feb; 46(2):75-80. PubMed ID: 20393635
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.
Vakily M; Zhang W; Wu J; Atkinson SN; Mulford D
Curr Med Res Opin; 2009 Mar; 25(3):627-38. PubMed ID: 19232037
[TBL] [Abstract][Full Text] [Related]
12. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy.
Metz DC; Vakily M; Dixit T; Mulford D
Aliment Pharmacol Ther; 2009 May; 29(9):928-37. PubMed ID: 19298580
[TBL] [Abstract][Full Text] [Related]
13. Dual Delayed-Release Dexlansoprazole for Healing and Maintenance of Healed Erosive Esophagitis: A Safety Study in Adolescents.
Gremse D; Gold BD; Pilmer B; Hunt B; Korczowski B; Perez MC
Dig Dis Sci; 2019 Feb; 64(2):493-502. PubMed ID: 30390234
[TBL] [Abstract][Full Text] [Related]
14. Dexlansoprazole MR: a review.
Hershcovici T; Jha LK; Fass R
Ann Med; 2011 Aug; 43(5):366-74. PubMed ID: 21366513
[TBL] [Abstract][Full Text] [Related]
15. Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.
Emerson CR; Marzella N
Clin Ther; 2010 Aug; 32(9):1578-96. PubMed ID: 20974316
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.
Fass R; Chey WD; Zakko SF; Andhivarothai N; Palmer RN; Perez MC; Atkinson SN
Aliment Pharmacol Ther; 2009 Jun; 29(12):1261-72. PubMed ID: 19392864
[TBL] [Abstract][Full Text] [Related]
17. The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease.
Dabholkar AH; Han C; Paris MM; Perez MC; Atkinson SN; Peura DA
Aliment Pharmacol Ther; 2011 Feb; 33(3):366-77. PubMed ID: 21118280
[TBL] [Abstract][Full Text] [Related]
18. Dexlansoprazole MR.
Aslam N; Wright R
Expert Opin Pharmacother; 2009 Oct; 10(14):2329-36. PubMed ID: 19708852
[TBL] [Abstract][Full Text] [Related]
19. Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease.
Wu MS; Tan SC; Xiong T
Aliment Pharmacol Ther; 2013 Jul; 38(2):190-201. PubMed ID: 23718547
[TBL] [Abstract][Full Text] [Related]
20. Treatment of gastroesophageal reflux disease: two new oral formulations dexlansoprazole MR and esomezol (esomeprazole strontium).
Parekh PJ; Oldfield EC; Johnson DA
Expert Opin Pharmacother; 2014 Jun; 15(9):1215-22. PubMed ID: 24749891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
